Presti Mariyamma Varghese reported acquisition or exercise transactions in this Form 4 filing.
OptimizeRx Corp director Presti Mariyamma Varghese received a grant of 17,258 restricted stock units (RSUs) of common stock. The award was made at no cash cost per unit and increases her direct holdings to 30,318 shares after the transaction. The RSUs represent a contingent right to receive shares that will vest in full on the earlier of the first anniversary of the grant date or the date of OptimizeRx’s next annual meeting of shareholders.
Spangler Patrick D reported acquisition or exercise transactions in this Form 4 filing.
OptimizeRx Corp director Patrick D. Spangler received an equity award of 34,517 shares of common stock in the form of restricted stock units. The units carry a contingent right to receive OptimizeRx common stock and will vest in full on the earlier of the first anniversary of the June 9, 2026 grant date or the company’s next annual meeting of shareholders. Following this grant, he directly owns 78,732 shares of common stock.
Vos Ellen O'Connor reported acquisition or exercise transactions in this Form 4 filing.
OptimizeRx Corp director Ellen O'Connor Vos received an equity grant of 34,517 shares of common stock in the form of restricted stock units. The award was granted for no cash consideration as compensation and increases her direct holdings to 107,159 common shares.
The restricted stock units will vest in full on the earlier of the first anniversary of the grant date or the date of OptimizeRx's next annual meeting of shareholders, aligning her compensation with future company performance and shareholder timelines.
WASSON GREGORY D reported acquisition or exercise transactions in this Form 4 filing.
OptimizeRx Corp director Gregory D. Wasson received an equity award of 34,517 restricted stock units (RSUs). These RSUs represent a contingent right to receive shares of OptimizeRx common stock as part of his director compensation, at no cash purchase price.
The RSUs will vest in full on the earlier of the first anniversary of the grant date or the date of the company’s next annual meeting of shareholders. After this grant, Wasson directly holds 91,700 shares of OptimizeRx common stock, reflecting his ongoing equity stake in the company.
Presti Mariyamma Varghese reported acquisition or exercise transactions in this Form 4 filing.
OptimizeRx Corp director Mariyamma Varghese Presti reported an award of equity-based compensation. She received 13,060 restricted stock units representing a contingent right to receive shares of OptimizeRx common stock, granted at no cash cost on May 1, 2026.
The restricted stock units will vest in full on the first anniversary of the grant date. Following this grant, the filing shows direct ownership of 13,060 shares or share equivalents tied to this award.
OptimizeRx Corporation reported that Chief Commercial Officer Theresa Greco will separate from the company effective June 15, 2026, transitioning into an advisory role for twelve months through June 15, 2027. On June 1, 2026, she and the company entered into a Separation and Advisory Agreement, which becomes effective June 9, 2026 if not revoked.
Ms. Greco will receive continuation of her $380,000 annual base salary for 12 months, a one-time cash bonus equal to her $209,000 annual bonus target, and reimbursement of COBRA premiums for health, dental, and vision coverage for up to 12 months. During the advisory period, her previously granted equity will continue to vest on the normal schedule, and she may receive a special bonus if a change in control occurs under a prior bonus agreement.
The agreement includes a general release of claims, a 12‑month non‑compete and non‑solicitation restrictions tied to a Business Protection Agreement, and requires her to comply with company policies while serving as an advisor.
OptimizeRx Corp Chief Commercial Officer Theresa Greco reported routine tax-related share dispositions. On May 15, 2026, the company withheld 879 and 914 shares of Common Stock at $5.21 per share to cover her tax obligations upon vesting of restricted stock units. The footnote explains these withholdings are treated as dispositions under Section 16 rules, but they were not open-market sales and reflect standard equity-compensation tax treatment.
OptimizeRx Corp Chief Executive Officer Stephen L. Silvestro reported a tax-related share disposition tied to vesting equity awards. On this Form 4, 5,219 shares of common stock were withheld by the company on May 15, 2026 at a value of $5.21 per share to cover his tax withholding obligations upon vesting of restricted stock units. The filing notes this withholding is treated as a disposition under Section 16 rules, but it is not an open-market sale. After the transaction, Silvestro directly owned 185,288 shares of OptimizeRx common stock, so the withheld amount represents a small portion of his overall reported holdings.
OptimizeRx reported a smaller quarterly loss as it improved margins despite lower revenue. Net revenue for the three months ended March 31, 2026 was $19,844, down 10% from $21,928 a year earlier, mainly due to the wind-down of a low-margin managed service program and reduced spend from a major customer.
Expenses fell 19% to $19,448, driven by a sharp drop in cost of revenues to $4,912, or about 25% of revenue, versus $8,584 previously. Income from operations was $396 compared with a loss of $2,102, and net loss narrowed to $495 from $2,199.
Cash and cash equivalents were $20,169 and working capital was $45,706 as of March 31, 2026. Long-term debt totaled $23,598 under a term loan bearing 12.4% interest, which the company refinanced on May 7, 2026 with a new $25,000 term loan and a $10,000 revolving facility at SOFR plus 1.75–2.5%. There were 18,765,075 common shares outstanding as of April 29, 2026. Management continues to work on remediating a remaining material weakness related to controls over data from one third-party service organization.
OptimizeRx Corporation reported mixed but improving first-quarter 2026 results and refinanced its debt on more favorable terms. Q1 2026 revenue was $19.8 million, down 10% from $21.9 million a year earlier, but the GAAP net loss narrowed to $0.5 million from $2.2 million. Non-GAAP net income rose to $2.7 million and adjusted EBITDA more than doubled to $3.3 million.
The company updated its 2026 outlook to revenue of $95–$100 million and maintained adjusted EBITDA guidance of $21–$25 million. It ended March 31, 2026 with $20.2 million in cash and $23.6 million of debt. After quarter-end, OptimizeRx closed a new $35 million senior secured facility with Fifth Third Bank, replacing its prior term loan, lowering its interest rate by 625 basis points and targeting about $1.5 million in annual interest savings, alongside efficiency initiatives expected to deliver $3 million in annualized cost savings.